Contact us Demo our platform

METABOLON @

European Stroke Organisation Conference
(ESOC) 2024

  • Basel, Switzerland
  • Booth B17
  • May 15 - May 17, 2024

Metabolon is pleased to exhibit at the European Stroke Organisation Conference (ESOC) 2024.

We’re thrilled to announce our participation in the European Stroke Organisation Conference (ESOC) 2024, taking place in Basel, Switzerland. The European Stroke Organisation (ESO) is a pan-European society of stroke researchers and physicians, national and regional stroke societies. The aim of the ESO is to reduce the burden of stroke by changing the way that stroke is viewed and treated, which can only be achieved by professional and public education, and by making institutional changes.

Stroke is a complex neurological condition with diverse metabolic implications. At Metabolon, we specialize in identifying metabolic biomarkers associated with stroke and other neurological disorders. Visit our booth to learn how our metabolomics services can accelerate biomarker discovery and improve patient outcomes. Whether you’re a clinician, researcher, or industry professional, we invite you to join us on the forefront of metabolomics innovation.

For more event information, you can read visit the official event website or read the official program.

Join us at Booth B17

Don’t miss the opportunity to connect with Metabolon at ESOC 2024 in Basel, Switzerland. Stop by booth B17 to meet our team, explore our metabolomics solutions, and discover how we can propel your research forward. Schedule a meeting here to guarantee 1:1 time with a metabolomics expert.

Event Location

Congress Center Basel
Messepl. 21,
4058 Basel,
Switzerland
Google Maps

Why Metabolomics: Your Guide to Metabolomics

In this guide, we explore the ins and outs of one of the most powerful omics tools in any scientist’s toolbox, one that can complement any existing workflow and help realize the full potential of other omics methods: metabolomics.

Read now

Schedule a Meeting

Meet the Reps Attending ESOC 2024

Antoine Briffaux

Antoine Briffaux

Director, International Sales & Strategic Accounts

Antoine Briffaux serves as the Director of International Sales & Strategic Accounts at Metabolon, overseeing the commercial operations in Europe and Asia and managing partnerships within the BioPharma sector. He holds an MBA from the ULB Solvay Brussels School of Economics & Management, alongside a BSc/MSc in Biology and Psychology from the Free University of Brussels (VUB).

Before his current role at Metabolon, Antoine was the Global Head of Sales at HistoGeneX, a service laboratory specializing in histopathology and genomics. Additionally, he led Global Project Management at SGS Life Sciences, where he was responsible for overseeing clinical trial operations across the company’s global network. His extensive background in biopharmaceutical services and international business strategy has equipped him with a unique blend of scientific expertise and commercial acumen.

Natasa Giallourou

Natasa Giallourou

Field Metabolomics Specialist

Dr Natasa Giallourou is a Field Metabolomics Scientist supporting Metabolon’s International Business activities. She provides scientific counsel for metabolomics applications in the biopharma and academic sectors. Natasa obtained her PhD in Metabolomics from the University of Reading and holds an MSc in Nutrition and Health from Wageningen University and a BSc in Biology from the University of Leeds.

Prior to joining Metabolon, Natasa served as a Marie Skłodowska-Curie Postdoctoral Fellow at biobank.cy. Her research projects involved integrating metabolomic data with other ‘omics’ data in population-based studies, with a focus on identifying biomarkers for complex diseases. She has also worked as a Postdoctoral Research Associate at Imperial College London, where she specialized in utilizing metabolic phenotyping to address global health challenges, particularly in the field of public health nutrition.

Natasa sits on the Board of Directors of the International Metabolomics Society and is also an advisor to the Early-career Member’s Network for young metabolomics scientists.

Raffy Demirdjian

Raffy Demirdjian

Business Development Director

Raffy Demirdjian is a seasoned sales professional with a passion for innovation and leadership in the Life Sciences and Biotechnology field. Specializing in metabolomics and various omics, Raffy is dedicated to assisting clients in finding optimal solutions and advancing their projects in this rapidly evolving field. 

With a solid background in academic research and hands-on experience in R&D within the industry, Raffy brings a wealth of knowledge and expertise to every project. His proactive approach and responsiveness ensure that clients receive tailored, high-quality solutions that align perfectly with their R&D objectives. 

Based in the Paris region, and covering France and Belgium, Raffy is eager to engage with clients face to face, providing personalized consultations to discuss and strategize metabolomics projects. His commitment to excellence and customer satisfaction makes him a trusted partner for organizations seeking to excel in the realm of life sciences research and development. 

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.